Protective actions of aspirin-triggered (17R) resolvin D1 and its analogue, 17R-Hydroxy-19-Para-Fluorophenoxy-Resolvin D1 Methyl Ester, in C5a-Dependent IgG immune complex-induced inflammation and lung injury

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3769-3778

  Tang, Huifang ^a,b   Liu, Yanlan ^a   Yan, Chunguang ^a   Petasis, Nicos A ^c   Serhan, Charles N ^a   Gao, Hongwei ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXY 19 PARA FLUOROPHENOXY RESOLVIN D1 METHYL ESTER; ANTIINFLAMMATORY AGENT; ASPIRIN TRIGGERED RESOLVIN D1; CCAAT ENHANCER BINDING PROTEIN BETA; CHEMOKINE; COMPLEMENT COMPONENT C5A; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID; CCAAT ENHANCER BINDING PROTEIN; CCL3 PROTEIN, MOUSE; DOCOSAHEXAENOIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RESOLVIN D1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; IMMUNE COMPLEX DEPOSITION; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; LUNG INJURY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PNEUMONIA; ACUTE LUNG INJURY; ANIMAL; ANTIGEN ANTIBODY COMPLEX; CELL LINE; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; LUNG LAVAGE; NEUTROPHIL; PATHOLOGY;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGEN-ANTIBODY COMPLEX; ASPIRIN; BRONCHOALVEOLAR LAVAGE FLUID; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE; CHEMOKINE CCL3; COMPLEMENT C5A; CYTOKINES; DOCOSAHEXAENOIC ACIDS; IMMUNOGLOBULIN G; MACROPHAGES, ALVEOLAR; MICE; NEUTROPHILS; NF-KAPPA B; PNEUMONIA;

EID: 84907222918     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400942     Document Type: Article

References (47)

1. Gao, H., T. Neff, and P. A. Ward. 2006. Regulation of lung inflammation in the model of IgG immune-complex injury. Annu. Rev. Pathol. 1: 215-242.
2. Guo, R. F., and P. A. Ward. 2002. Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radic. Biol. Med. 33: 303-310.
3. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.
4. Recchiuti, A. 2013. Resolvin D1 and its GPCRs in resolution circuits of inflammation. Prostaglandins Other Lipid Mediat. 107: 64-76.
5. Sun, Y. P., S. F. Oh, J. Uddin, R. Yang, K. Gotlinger, E. Campbell, S. P. Colgan, N. A. Petasis, and C. N. Serhan. 2007. Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282: 9323-9334.
6. Rius, B., E. Titos, E. Morán-Salvador, C. López-Vicario, V. García-Alonso, A. González-Pé riz, V. Arroyo, and J. Clària. 2014. Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. FASEB J. 28: 836-848.
7. Lima-Garcia, J. F., R. C. Dutra, K. da Silva, E. M. Motta, M. M. Campos, and J. B. Calixto. 2011. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. 164: 278-293.
8. Xu, Z. Z., L. Zhang, T. Liu, J. Y. Park, T. Berta, R. Yang, C. N. Serhan, and R. R. Ji. 2010. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16 : 592-597, 1p following 597.
9. Bang S.,S. Yoo,T. J. Yang,H. Cho,S. W,Hwang., 2012. 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to per ipheral antinociception. Br. J. Pharmacol., 165, 683-692.
10. Spite, M., L. Summers, T. F. Porter, S. Srivastava, A. Bhatnagar, and C. N. Serhan. 2009. Resolvin D1 controls inflammation initiat ed by glutathionelipid conjugates formed during oxidative stress. Br. J. Pharmacol. 158: 1062-1073.
11. Tang, Y., M. J. Zhang, J. Hellmann, M. Kosuri, A. Bhatnagar, and M. Spite. 2013. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62: 618-627.
12. Jin, Y., M. Arita, Q. Zhang, D. R. Saban, S. K. Chauhan, N. Chiang, C. N. Serhan, and R. Dana. 2009. Anti-angiogenesis effect of the novel antiinflammatory and pro-resolving lipid mediators. Invest. Ophthalmol. Vis. Sci. 50: 4743-4752.
13. Duffield, J. S., S. Hong, V. S. Vaidya, Y. Lu, G. Fredman, C. N. Serhan, and J. V. Bonventre. 2006. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177: 5902-5911.
14. Kasuga, K., R. Yang, T. F. Porter, N. Agrawal, N. A. Petasis, D. Irimia, M. Toner, and C. N. Serhan. 2008. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J. Immunol. 181: 8677-8687.
15. Bent o, A. F., R. F. Claudino, R. C. Dutra, R. Marcon, and J. B. Calixto. 2011. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice . J. Immunol. 187: 1957-1969.
16. Chen, F., X. H. Fan, Y. P. Wu, J. L. Zhu, F. Wang, L. L. Bo, J. B. Li, R. Bao, and X. M. Deng. 2014. Resolvin D1 improves survival in experim ental sepsis through reducing bacterial load and preventing excessive activation of inflammatory response. Eur. J. Clin. Microbiol. Infect. Dis. 33: 457-464.
17. Eickmeier, O., H. Seki, O. Haworth, J. N. Hilberath, F. Gao, M. Uddin, R. H. Croze, T. Carlo, M. A. Pfeffer, and B. D. Levy. 2013. Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol. 6: 256-266.
18. Rogerio, A. P., O. Haworth, R. Croze, S. F. Oh, M. Uddin, T. Carlo, M. A. Pfeffer, R. Priluck, C. N. Serhan, and B. D. Levy. 2012. Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J. Immunol. 189: 1983- 1991.
19. Serhan, C. N., and N. A. Petasis. 2011. Re solvins and protectins in inflammation resolution. Chem. Rev. 111: 5922-5943.
20. Gao, H., R. F. Guo, C. L. Speyer, J. Reuben, T. A. Neff, L. M. Hoesel, N. C. Riedemann, S. D. McClintock, J . V. Sarma, N. Van Rooijen, et al. 2004. Stat3 activation in acute lung injury. J. Immunol. 172: 7703-7712.
21. Tang, H., C. Yan, J. Cao, J. V. Sarma, E. B. Haura, M. Wu, and H. Gao. 2011. An essential role for Stat3 in regulating IgG immune complex-induced pulmonary inflammation. FASEB J. 25: 4292-4300.
22. Mulligan, M. S., M. L. Jones, A. A. Vaporciyan, M. C. Howard, and P. A. Ward. 1993. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J. Immunol. 151: 5666-5674.
23. Mulligan, M. S., J. M. Hevel, M. A. Marletta, and P. A. Ward. 1991. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc. Natl. Acad. Sci. USA 88: 6338-6342.
24. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23: 821-852.
25. Mulligan, M. S., E. Schmid, B. Beck-Schimmer, G. O. Till, H. P. Friedl, R. B. Brauer, T. E. Hugli, M. Miyasaka, R. L. Warner, K. J. Johnson, and P. A. Ward. 1996. Requirement and role of C5a in acute lung inflammatory injury in rats. J. Clin. Invest. 98: 503-512.
26. Shushakova, N., J. Skokowa, J. Schulman, U. Baumann, J. Zwirner, R. E. Schmidt, and J. E. Gessner. 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 110: 1823-1830.
27. Lentsch, A. B ., B. J. Czermak, N. M. Bless, and P. A. Ward. 1998. NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement. Am. J. Pathol. 152: 1327-1336.
28. Lentsch, A. B., T. P. Shanley, V. Sarma, and P. A. Ward. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J. Clin. Invest. 100: 2443-2448.
29. Yan, C., M. Zhu, J. Staiger, P . F. Johnson, and H. Gao. 2012. C5a-regulated CCAAT/enhancer-binding proteins b and d are essential in Fcg receptormediated inflammatory cytokine and chemokine production in macrophages. J. Biol. Chem. 287: 3217-3230.
30. Yan, C., M. Wu, J. Cao, H. Tang, M. Zhu, P. F. Johnson, and H. Gao. 2012. Critical role for CCAAT/enhancer-binding protein b in immune complexinduced acute lung injury. J. Immunol. 189: 1480-1490.
31. Serhan, C. N. 2007. Resolution phase of inflammation: novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25: 101-137.
32. Recchiuti, A., S. Krishnamoorthy, G. Fredman, N. Chiang, and C. N. Serhan. 2011. MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J. 25: 544-560.
33. Lukacs, N. W., and P. A. Ward. 1996. Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. Adv. Immunol. 62: 257-304.
34. Li, Y., J . Dalli, N. Chiang, R. M. Baron, C. Quintana, and C. N. Serhan. 2013. Plasticity of leukocytic exudates in resolving acute inflammation is regulated by microRNA and proresolving mediators. Immunity 39: 885-898.
35. Prakash, A., K. R. Mesa, K. Wilhelmsen, F. Xu, J. M. Dodd-o, and J. Hellman. 2012. Alveolar macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfusion injury in mice. Anesthesiology 1 17: 822-835.
36. Frank, J. A., C. M. Wray, D. F. McAuley, R. Schwendener, and M. A. Matthay. 2006. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L1191-L1198.
37. Zhao, M., L. G. Fernandez, A. Doctor, A. K. Sharma, A. Zarbock, C. G. Tribble, I. L. Kron, and V. E. Laubach. 2006. Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L1018-L1026.
38. Naidu, B. V., B. Krishnadasan, A. S. Farivar, S. M. Woolley, R. Thomas, N. Van Rooijen, E. D. Verrier, and M. S. Mulligan. 2003. Early activation of the alveolar macrophage is critical to the development of lung ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 126: 200-207.
39. Lentsch, A. B., B. J. Czermak, N. M. Bless, N. Van Rooijen, and P. A. Ward. 1999. Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. Am. J. Respir. Cell Mol. Biol. 20: 692-698.
40. Crockett, E. T., C. Remelius, K. Hess, and H. Al-Ghawi. 2004. Gene deletion of P-selectin and ICAM-1 does not inhibit neutrophil infiltration into peritoneal cavity following ceca l ligation-puncture. BMC Clin. Pathol. 4: 2.
41. Cantwell, C. A., E. Sterneck, and P. F. Johnson. 1998. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol. Cell. Biol. 18: 2108-2117.
42. Shanley, T. P., H. Schmal, H. P. Friedl, M. L. Jones, and P. A. Ward. 1995. Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J. Immunol. 154: 3454-3460.
43. Norling, L. V., J. Dalli, R. J. Flower, C. N. Serhan, and M. Perretti. 2012. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler. Thromb. Vasc. Biol. 32: 1970 -1978.
44. Krishnamoorthy, S., A. Recchiuti, N. Chiang, G. Fredman, and C. N. Serhan. 2012. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am. J. Pathol. 180: 2018-2027.
45. Krishnamoorthy, S., A. Recchiuti, N. Chiang, S. Yacoubian, C. H. Lee, R. Yang, N. A. Petasis, and C. N. Serhan. 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107: 1660-1665.
46. Lukacs, N. W., M. M. Glovsky, and P. A. Ward. 2001. Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity. Am. J. Physiol. Lung Cell. Mol. Physiol. 280: L512-L518.
47. Cappelletti, M., T. Alonzi, E. F attori, C. Libert, and V. Poli. 1996. C/EBPbeta is required for the late phases of acute phase genes induction in the liver and for tumour necrosis factor-alpha, but not interleukin-6, regulation. Cell Death Differ. 3: 29- 35.